Cargando…

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors

AIM: Sacubitril-valsartan has proven beneficial in heart failure with reduced ejection fraction. Guidelines recommend initiating half-dose sacubitril-valsartan before up-titration even to patients already on target dose angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norberg, Helena, Bergdahl, Ellinor, Lindmark, Krister
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739794/ https://www.ncbi.nlm.nih.gov/pubmed/31772613 http://dx.doi.org/10.1155/2019/6745074

Ejemplares similares

Eligibility of sacubitril–valsartan in a real‐world heart failure population: a community‐based single‐centre study
por: Norberg, Helena, et al.
Publicado: (2018)

A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study
por: Norberg, Helena, et al.
Publicado: (2020)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Obstacles to mineralocorticoid receptor antagonists in a community‐based heart failure population
por: Jonsson, Anna, et al.
Publicado: (2018)

Evaluating the safety and tolerability of inpatient sacubitril/valsartan initiation in a community hospital
por: Peppin, Katie L., et al.
Publicado: (2020)

Effect of the angiotensin receptor–neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide
por: Ayalasomayajula, Surya, et al.
Publicado: (2018)

Health‐related quality of life in patients with heart failure eligible for treatment with sacubitril–valsartan
por: Holmlund, Lena, et al.
Publicado: (2019)

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
por: Mohanty, April F., et al.
Publicado: (2021)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Implementation of sacubitril/valsartan in Sweden: clinical characteristics, titration patterns, and determinants
por: Fu, Michael, et al.
Publicado: (2020)

Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF
por: Visco, Valeria, et al.
Publicado: (2022)

Mineralocorticoid receptor antagonists use in patients with heart failure and impaired renal function
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2021)

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
por: Hernandez, Adrian V., et al.
Publicado: (2023)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Clinical evidence of initiating a very low dose of sacubitril/valsartan: a prospective observational analysis
por: Kim, Hyoeun, et al.
Publicado: (2021)

Safety and tolerability of Sacubitril/Valsartan in heart failure patient with reduced ejection fraction
por: Khan, Muhammad Nauman, et al.
Publicado: (2023)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System
por: Simko, Fedor, et al.
Publicado: (2022)

Comparison of creatinine‐based methods for estimating glomerular filtration rate in patients with heart failure
por: Jonsson, Anna, et al.
Publicado: (2020)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

Efficacy and safety of low‐dose sacubitril/valsartan in heart failure patients: A systematic review and meta‐analysis
por: Chen, Wen‐Wen, et al.
Publicado: (2023)

In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor
por: Jovanović, Jelena Đorović, et al.
Publicado: (2022)

Motives, frequency, predictors and outcomes of MRA discontinuation in a real-world heart failure population
por: Jonsson Holmdahl, Anna, et al.
Publicado: (2022)

Sacubitril/valsartan versus angiotensin inhibitors and arrhythmia endpoints in heart failure with reduced ejection fraction
por: Fernandes, Amanda D.F., et al.
Publicado: (2021)

The efficacy and safety of Sacubitril/Valsartan on pulmonary hypertension in hemodialysis patients
por: Zhao, Cong, et al.
Publicado: (2022)

Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization
por: Langenickel, Thomas H., et al.
Publicado: (2016)

Drug-Induced Liver Injury From Sacubitril-Valsartan Versus a Single Dose of Acarbose
por: Achuthanandan, Supraja, et al.
Publicado: (2022)

Successful treatment of doxorubicin-induced cardiomyopathy with low-dose sacubitril/valsartan: a case report
por: Bell, Elisabeth, et al.
Publicado: (2022)

Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort
por: López‐Azor, Juan Carlos, et al.
Publicado: (2019)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
por: Lefkowitz, Martin P
Publicado: (2015)

Angiotensin II Receptor–Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats
por: Seki, Takunori, et al.
Publicado: (2017)

Haemodynamic Effects of Sacubitril/Valsartan Initiation in Outpatients with Chronic Heart Failure
por: Fröhlich, Hanna, et al.
Publicado: (2022)

Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
por: Tan, Nicholas Y., et al.
Publicado: (2021)

Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure
por: Sohani, Zahra N., et al.
Publicado: (2023)

Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis
por: Yang, Pei, et al.
Publicado: (2022)

Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose
por: Pharithi, Rebabonye B., et al.
Publicado: (2020)

Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real‐world study
por: Wang, Chen, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a40ot7ci2dacpf24c1ielg4jl2